Date post: | 17-Mar-2016 |
Category: |
Documents |
Upload: | research-on-global-markets |
View: | 219 times |
Download: | 4 times |
Healthcare Sector in India Monthly Update
October 2012
Top Story BITS Pilani comes up with 1st indigenous low cost glucometer BITS Pilani scientists have come up with India’s 1st indigenous glucometer which has passed the final evaluation test conducted by the Indian Council of Medical Research (ICMR). The device comes with the unique feature of costing as low as INR 2 per test. The cost thus is rated much below of what Indian Health Ministry had promised of developing ‐ a diabetic testing chip that would cost INR 5 per test. Additionally, the device is capable of providing speedy results in as less as 10 seconds with 1,000 times lesser blood than what prevailing lucometers require. Hence the entire procedure from finger pricking to loading the blood
k lgsample to flashing of the result may ta e up about a minute on y. The prototype device is expected to be ready by Dec 2012 which will then go through a onth long multi‐centre efficacy study in various labs before it gets rolled out for mass m
production. The huge diabetic population of India will be benefitted since the latest test will not require repeated use of expensive testing strips due to its cost effectiveness. News Update
General SightLife partners with L V Prasad Eye Institute A corneal tissue cutting centre has been established at the Ramayamma International Eye Bank at L V Prasad Eye Institute (LVPEI) in Hyderabad. The facility is an initiative by the eattle based global healthcare organization SightLife that has been making efforts to Simprove surgical techniques for better outcomes. Descemet’s Stripping Endothelial Keratoplasty (DSEK) which is currently being considered as the most effective treatment for corneal edema is dependent on superior equipments and trained professionals. The equipments required for lamellar dissection of the donor cornea requires a host of special equipments that are unavailable in Indian hospitals. SightLife here s making a serious effort by partnering with India based eye banks to provide the less nvasive and reduced rejection risk treatment to Indians. ii Dabur to relaunch 30Plus The world’s largest ayurveda company Dabur will be re‐launching its once popular over‐the‐counter (OTC) revitalize brand ‘30‐Plus’ that it acquired in May 2011. Launched in 1990s, the rand fizzed out from the popularity chart as its promoter Ajanta Pharma started oncentrating in promotion of prescription drugs. bc
Healthcare Sector – Monthly Update
The re‐launch of the product has been planned by Dabur with the intention of revamping and expanding its OTC portfolio by launching new products in emerging therapeutic areas. The product will be competing with Ranbaxy’s popular brand Revital that has a significant share n energizer products segment which alone registered a growth rate of 25% in the past inancial year. if India’s first indigenous insulin pen French drug maker Sanofi SA subsidiary Sanofi India Ltd. has given to India its first ever locally manufactured insulin pen. The product branded as AllStar has been manufactured especially keeping Indian users in mind. The product is not only reusable but is being aunched at a budget price of INR 650 only that comes within a patient’s affordability. The roduct will also be made available in the overseas market. lp Krishna Hospital to merge with Shalby Hospitals Yogeshwar Healthcare Ltd, which initiated operation of Ghuma located Krishna Hospital in the year 2000 gave to Ahmadabad its first corporate hospital. The hospital is in the process of getting merged with Ahmadabad based Shalby Hospitals. Shalby has acquired a majority take of 86% that is being rumored to be valued at INR 750 mn to INR 850 mn. The stransaction thus makes Shalby the biggest corporate hospital in Ahmadabad with 450 beds. On completion of the formalities, Krishna Hospital will be expanded into a 250‐bedded multi‐pecialty hospital. The upgradation of Krishna Hospital is expected to help in diverting the atient traffic from Shalby Hospital which faces a perennial shortage of beds. sp SMS Pharmaceuticals sells off manufacturing plant to Mylan Global healthcare company Mylan Laboratories has bought Hyderabad based SMS Pharmaceuticals’ Vishakhapatnam located manufacturing unit for INR 1.73 bn. The proceeds from the transaction will be used by SMS Pharmaceuticals for clearing off some of its past ebts, cutting down overhead costs along with upgrading its existing manufacturing facilities dand strengthening its working capital base. The transaction is expected to improve both the companies’ position in market. On one hand SMS Pharmaceuticals would be able to do away with its past debts and strengthen its urrently operative manufacturing units, and on the other hand Mylan’s acquisition of the anufacturing unit is an expansion for the generic pharma manufacturer.
cm Micro Labs Ltd. introduces Hypotab Karnataka based Micro Labs Ltd. has penetrated the Indian hypoglycemic market with its new dextrose drug ‘Hypotab’. The drug has been identified to be suitable for mild to oderate hypoglycemia conditions. The company has invested INR 55 mn for production of he drug at its Puducherry unit that has an installed capacity of 1mn tabs/month. mt
Healthcare Sector – Monthly Update
It uses the advanced AbMax technology that helps to pulverize the active ingredient dextrose o about 20 micron particle size for immediate absorption into the blood stream. The ompany is expecting a turn over of INR 42 mn from this latest addition to its drug portfolio. tc Intas group seeking merger of its group companies Ahmadabad based Intas Group is seeking to amalgamate 4 group companies for which it has already filed a petition in the Gujarat High Court. The companies to be amalgamated under ections 391 to 394 of the Companies Act, 1956, include Intas Pharmaceuticals Ltd., Astorn sResearch Ltd., Intas Biopharmaceuticals Ltd. and Celestail Biologicals Ltd. The parent company will be holding meeting of all shareholders and secured and unsecured creditors to get their consent on the amalgamation proposal of the concerned companies. he consolidation will possibly help in bringing about cost efficiency and enhancement of evenue through gain in market share. Tr Fortis combines luxury and entertainment with hospital Fortis has forged ahead in the hospital industry by its inauguration of ‘hospital mall’ – the Fortis Memorial Research Institute (FMRI) in Gurgaon. The ‘next generation concept hospital’ houses multi‐specialty hospital with shopping mall that will have 18 retail and food utlets. The 450 bedded FMRI is equipped with 25 operating rooms along with a full‐fledged ostem‐cell lab. The Fortis group has clear plans of expanding the facility not only in terms of space but also facilities. The number of beds is expected to go up to 1,000 and will soon be introducing robotic surgery and organ transplant facilities. In luxury segment, it will be introducing dditional facilities of health club, spa and movie lounge. a News Update
Regulatory India Russia aiming to boost bilateral pharmaceutical trade India and Russia have come together to liberalize the registration process of new drugs to improve bilateral trade between the countries. The countries are expected to sign a memorandum of understanding (MoU) for a quicker and easier registration for drugs and pharmaceutical products. This comes after the MoU the countries had signed in 2010 for ooperation in pharma trade and industry for which both are currently working towards csetting up a task force to exchange knowledge and views. Indian pharmaceutical industry is trying to bank upon the heavily import dependent Russian pharmaceutical market. With the new MoU, it is expected to do away with the lengthy
Healthcare Sector – Monthly Update
process and non‐acceptance of clinical trials data generated by other countries while registering their drugs in Russian pharmaceutical market. Chhattisgarh implements strict measures against fake drugs The Chhattisgarh Food Drug Control Administration (FDCA) has taken a major step to control the circulation of spurious and substandard drugs along with controlling red tapism for various processes prevalent in pharmaceutical industry. In regard to spurious and substandard drugs circulating in the market, FDCA plans to publish the data online with their
etails. batch numbers and other relevant d
The government has put in place a unique software Extended Laboratory Node through National Informatics Centre (NIC) to fulfill its plan. The Chhattisgarh FDCA initiated such a move taking a cue from the Gujarat government that is currently aiding Chhattisgarh for successful implementation of the project. News Update
Expansion Plans AHLL to invest for expansion in number of clinics The subsidiary unit of Apollo Hospitals Enterprise Ltd., Apollo Health and Lifestyle Ltd. (AHLL) is in plans to raise the number of its branded healthcare clinics. It is planning for a 5‐fold increase from the current 90 such operating clinics in the next 3‐5 years. The clinics will e spread across the metro and other prominent cities of the country for which AHLL has set baside INR 2.5 bn. The clinics that are being planned by the group will be owned by the company unlike the franchise mode of operation of the currently operative 90 clinics. Such a decision has been planned strategically in order to keep an eye on the quality of healthcare service being meted ut to its patients. With the rise in the number of clinics, the Apollo group is expecting a evenue surge from its Mar 2012 revenue of INR 0.36 bn to INR 5 bn. or Industry Expert Speak SightLife partners with L V Prasad Eye Institute – Dr. Gullapalli N Rao, Chairman of L V Prasad Eye Institute “The Ramayamma International Eye Bank will be the first centre in the Asia Pacific region to have taken a step in this direction to make the pre‐cut donor corneas available to all
Healthcare Sector – Monthly Update
interested corneal surgeons. This not only reduces the overall cost of the surgery for both the atients and the surgeons but also standardizes the procedure.” p BITS Pilani comes up with 1st indigenous low cost glucometer Suman Kapur, Biological Sciences Professor and Chief Developer of diagnostic tool, BITSPilani "The final evaluation took place on August 6 and we have been given the go‐ahead to create the prototype which will be ready latest by December. Most such devices need to undergo multi‐centre trials. So once the prototype is delivered, ICMR will commission studies in various labs to confirm the technology. Once through, we will either produce the machine ourselves or transfer the technology to a third party for mass production and introduction i nto the market."
Chhattisgarh implements strict measures against fake drugs K Subramanian, Food Safety Commissioner for Chhattisgarh and Controller Food and Drugs Administration "We have already started uploading the existing data and by Nov 15 we will complete the rocess. Subsequently, the data would be updated on day to day basis and our services would e launched by Dec." pb
Transaction Detail (Aug – Sep 2012)
Date Buyer Target Deal Size (INR mn)
% stake Deal Status Type of
Transaction
2 t 5th Oc2012
Fidelity India Capital
Trivitron Healthcare 4000 35‐40 Planned Private Equity
2 t 2nd Oc2012
Dr. Reddy's Laboratories
OctoPlus N.V. 1930 100 Planned Acquisition
1 t 7th Oc2012
Mylan Laboratories
SMS Pharmaceuticals’ Vishakhapatnam
located m g anufacturin
1730 N.A. Completed Acquisition
2 7th Sep2012
Norwest Venture Partners
Thyrocare Technologies 1200 10 Completed Private Equity
Healthcare Sector – Monthly Update
1 2th Sep2012
Avigo Capital Partners
Super Religare Laboratories 2,916.79 N.A. Planned Private Equity
1 2th Sep2012
IndoUS Venture Partners
Vyome Biosciences Pvt
Ltd. 185 N.A. Planned Private Equity
11th Sep 2012
Norwest Venture Partners
Thyrocare Technologies
Ltd 1166.71 10 Planned Private Equity
5th Sep 2012
Norwest Venture Partners
NationWide Primary He e althcar
S . ervices Pvt. Ltd
250 N.A. Completed Private Equity
30 g th Au2012 Hospira
Orchid Chemicals and P s harmaceutical
Ltd. Penicillin and Penem API business
11125.89 100 Completed Acquisition
29 g th Au2012 Pfizer
Strides Arcolab Injectable Drug
Unit 94600 100 Planned Acquisition
23 g rd Au2012
India Innovation Fund &
Indian Angel Network
Consure Medical N.A. N.A. Completed Private Equity
2 1st Aug2012
India Equity Partners
Axiss Dental N.A. N.A. Planned Private Equity
13 g th Au2012
Somerset Indus Capital Partners
Express Clinics Pvt. Ltd. N.A. N.A. Completed Private Equity
13 g th Au2012
Goldman Sachs &
New Enterprise Associates
Nova Medical Centres
2969.35 N.A. Completed Private Equity
Healthcare Sector – Monthly Update
13 g th Au2012
Sun Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries
32,552.9 34 Planned M&A
Annual Financial Results – Revenue (INR mn) – Major Healthcare Companies
Companies FY ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 1 6,492.50 23,932.70 2 7,947.70 21,483.0
Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5
Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7
Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0
Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0
Dr. Reddy’s Laboratories (DRL) 69,441.00 70,277.00 74,693.00 96,737.4
GlaxosmithKline Consumer Healthcare Ltd.
19,757.6 23,693.3 27,688.6 28,857.3
Glenmark Pharmaceuticals Ltd.
21,241.20 25,291.30 29,490.70 40,206.4
Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5
Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1
Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0
Opto Circuits (India) Ltd. 8,185.197 10,77 5.826 15,85 5.631 2 3,568.543
Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3
Ranbaxy Laboratories Ltd.
75,970.40 89,607.70 101,614.1 117,153.2
Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,6 57.9
Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1
Healthcare Sector – Monthly Update
Sun Pharmaceuticals Industries Ltd. 42,723.00 38,086.30 57,214.30 80,056.6
Torrent Pharmaceuticals Ltd. 16,306.60 19,160.40 22,264.80 26,959.2
Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0
Annual Financial Results – Income (INR mn) Major Healthcare Companies
Companies F Y ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0
Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0
Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9
Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4
Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0
Dr. Reddy’s Laboratories (DRL) ‐5,168.00 1,068.00 11,040.00 14,262.1
GlaxoSmithKline Consumer Healthcare Ltd. 2,327.8 2,998.5 3,552.1 3,765.6
Glenmark Pharmaceuticals Ltd.
1,916.60 3,244.70 4,532.10 4,603.5
Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6
Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5
Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7
Opto Circuits (India) Ltd. 2,087.3 2,603.0 3,672.5 5,718.8
Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0
Healthcare Sector – Monthly Update
Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5
Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6
Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4
Sun Pharmaceuticals Industries Ltd.
18,177.30 13,510.80 18,160.60 25,872.5
Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4
Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1
Quarterly Financial Results – Revenue (INR mn) – Major Healthcare Companies
Companies JulSep 2011
OctDec 2011
JanMar 2012
AprJun 2012
Biocon Ltd. 5,084.40 5 ,171.90 5,892.2 5,770.0
Blue Star Ltd. N.A. 5,896.9 N.A. N.A.
Cadila Healthcare Ltd. 12 0 ,196.4 13,524.60 14 .9 ,633 15 .0 ,161
Cipla Ltd. N.A. 17,580.00 N.A N.A.
Dabur India Ltd. 12,623.30 14,526.80 13,858.3 14,620.0
Dr. Reddy’s Laboratories (DRL) 2 2,678.00 2 7,692.00 2 6,584.0 25,406.0
GlaxoSmithKline Consumer Healthcare Ltd. 7,200.7 6,854.0 8,608.7 7,869.6
Glenmark Pharmaceuticals Ltd. 10,554.50 10,310.90 10,751.2 10,404.1
Jubilant life Sciences Ltd. 10,48 0.80 10,87 1.70 12,235.9 12,358.9
Lupin Ltd. 17,416.6 17,917.0 20,063.7 22,191.5
Healthcare Sector – Monthly Update
Nestle India Ltd. 1 9,631.00 1 9,633.2 2 0,558.7 19,865.8
Opto Circuits (India) Ltd. 5,620.4 6,112.9 6,627.0 7,150.6
Piramal Enterprises Ltd. 4,775.80 5,518.30 8,858.0 7,102.9
Ranbaxy Laboratories Ltd. 20 .3 ,955 37 .1 ,923 36,954.0 31 .6 ,740
Siemens India Ltd. N.A. N.A. 37 2 601.43 N.A.
Strides Arcolab Ltd 7,693.10 6,864.7 5,274.7 5,082.9
Sun Pharmaceuticals Industries Ltd. 1 8,946.00 2 1,451.30 2 3,299.3 26,581.4
Torrent Pharmaceuticals Ltd 6,833.3 6,965.9 6,686.8 7,356.0
Wockhardt Ltd. 11,105.30 12,086.70 12,413.90 14,258.2
Companies JulSep 2011
OctDec 2011
JanMar 2012
AprJun 2012
Biocon Ltd. 857.0 848.50 978.0 790.0
Blue Star Ltd. N.A. (327.6) N.A. N.A.
Cadila Healthcare Ltd. 1,0 0 26.8 1,492.10 1,708.8 1, 9 947.
Cipla Ltd. N.A. 2,699.10 N.A. N.A.
Dabur India Ltd. 1,738.6 1 ,728.20 1,705.1 1,494.0
Dr. Reddy’s Laboratories (DRL) 3,078.0 5 ,130.0 3,427.0 3,360.0
GlaxoSmithKline Consumer Healthcare Ltd. 1 ,030.3 591.0 1,319.7 1 ,066.0
Glenmark Pharmaceuticals Ltd. 558.6 461.20 1,482.7 782.8
Jubilant life Sciences Ltd. 793.6 ‐783.90 ‐635.3 50.1
Quarterly Financial Results – Income (INR mn) Major Healthcare Companies
Healthcare Sector – Monthly Update
Lupin Ltd. 2,668.70 2,350.60 1,556.4 2,803.9
Nestle India 2 ,611.80 2 ,308.30 2,757.3 2,459.7
Opto Circuits (India) Ltd. 1 ,210.6 1,250.8 2,093.5 1,380.2
Piramal Enterprises Ltd. 524.3 85.2 ‐386.8 40.8
Ranbaxy Laboratories Ltd. ‐4,645.8 ‐29 .7 ,827 1 2,467.6 ‐5,857.3
Siemens India Ltd. N.A. N.A. 3,040.0 N.A.
Strides Arcolab Ltd 464.7 684.1 6,420.7 904.8
Sun Pharmaceuticals Industries Ltd. 5 ,977.4 6 ,683.0 8 202.1 7,955.5
Torrent Pharmaceuticals Ltd 999.9 831.8 ‐16.5 1,018.5
Wockhardt Ltd. 1,275.80 2,128.10 ‐1,916.4 3,779.7
* denotes a change in financial year
Events Calendar
Indian Medical Tourism Conference and Alliance 2201
Date: 2
nd – enue:
3rd Nov 2012 V The Park Hotel, Hyderabad Organizer: IMTCA, ONE HealthCareTM Worldwide l Tourism
and Centre for medica Research
.comWebsite: http://www.imtca Contact No.: +91‐40‐64640323 E‐mail: [email protected]
Problem Solving Approach in Children with Cerebr Pal alsy
ate: 18 D th Nov, 2012 Venue: Me um, Prayag Sangeet Samiti, C
hta Auditori
Organizeivil Lines, Allahabad r: Samve
Website: dna
http://www.samvednatrust.com Contact Pers h on: Mr. Alok SingContact No.: +91 9453039213
Healthcare Sector – Monthly Update
5 Days Handson Workshop on Molecular Biotec o and ormatics hn logy Bioinf
Date: 19
th –enue:
23rd Nov 2012 V Pune Organizer: International Center for Stem Cells,
Cancer and Biotechnology (ICSCCB), Pune
Website:
g/workshopsht /tp://www.icsccb.or Contact r.Contact 8
Pe Mohan Singh rson: Prof. D Sheo No.: +91 95450 9202
E‐mail: [email protected] or [email protected]
Raps 2012: International Conference on Recent Advances a al Sciences in Ph rmaceutic
Date: 22
n
Venue: Wd – 24th Nov, 2012 arangal, Andhra Pradesh
Website: http://tinyurl.com/8fwmpb4
Clinical Trials in Southeast Asia (CTSE) 2012 Date: 23rd NVenue: T
ov 2012
Organizehe Sahara Star Hotel, Mumbai r: Clini
Website: cal Research
http://www.ssiconnects.org Contact Person: Amita Shah
No.: + 91 976 916 897Email: [email protected] Contact 2
5th National Conference of AIDS Society of India Date: 23rd –Venue: V Bangalore
25th Nov, 2012
Organizeivanta by Taj Yeshwantpur, r: AIDS a
Website: Society of Indi
http://www.asi‐asicon.com Contact Person: Dr. I. S. Gi
Fax No.:
ladaContact No.: +91 22 23061616
+91 22 23000016 Email: [email protected] / [email protected]
Healthcare Sector – Monthly Update
Research on India (ROI) is a leading source for market research on various sectors in India hat offers premium research content from worldwide publishers of market research treports. Contact us:
mW: https://www.researchonindia.co ; International: +91 (33) 4027 6214/5 T
E: India (Toll Free): 1800 102 1133: [email protected] Connect with Us
Disclaimer: This monthly update is published for general information only based on press rticles and company releases. Research on India has not independently verified any of nformation and is not responsible for any loss or damage arising from use of this document. ai
Healthcare Sector – Monthly Update